Kowalewski Adam, Borowczak Jędrzej, Choussy Olivier, Lesnik Maria, Badois Nathalie, Klijanienko Jerzy
Department of Pathology and Theranostics, Institut Curie, PSL University, Paris, France.
Department of Tumor Pathology, Oncology Centre, Prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland.
Cancer Cytopathol. 2025 Sep;133(9):e70041. doi: 10.1002/cncy.70041.
A comparative analysis of the International Academy of Cytology-International Agency for Research on Cancer-World Health Organization Reporting System for Head and Neck Cytopathology (WHO) and the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was performed.
A total of 2218 salivary gland fine-needle aspiration samples collected at the Institut Curie, Paris (1954-2022) were evaluated, with 1356 having histological follow-up. Samples were classified according to the MSRSGC (nondiagnostic [ND], nonneoplastic [NN], atypia of undetermined significance [AUS], benign neoplasm [BN], salivary gland neoplasm of uncertain malignant potential [SUMP], suspicious for malignancy [SM], and malignant [M]) and the WHO system (insufficient/inadequate/nondiagnostic, benign, atypical, neoplasm of uncertain malignant potential [NUMP], suspicious for malignancy [SM], and malignant [M]). The risk of malignancy (ROM) was calculated for each category, and diagnostic performance metrics were assessed.
In the MSRSGC, the ROM was ND, 50% (n = 2); NN, 16.8% (n = 149); AUS (no cases); BN, 4.3% (n = 514); SUMP, 50% (n = 2); SM, 56.1% (n = 66); and M, 98.2% (n = 623). In the WHO system, the ROM was insufficient/inadequate/nondiagnostic, 50% (n = 2); benign, 7.1% (n = 663); atypical (no cases); NUMP, 50% (n = 2); SM, 56.1% (n = 66); and M, 98.2% (n = 623). The WHO's "benign" category, which combines NN and BN, balanced the NN's higher ROM (16.8%) and BN's lower ROM (4.3%) into 7.1%. Excluding the ND and SUMP/NUMP categories, both systems demonstrated high diagnostic performance: sensitivity, 93.3%; specificity, 93.9%; positive predictive value, 94.2%; and negative predictive value, 92.9%.
Both systems effectively identify malignancy. The WHO system's merger of NN and BN into the benign category streamlines reporting and reduces variability, although it may mask clinically significant differences between nonneoplastic and benign neoplastic lesions.
对国际细胞学会 - 国际癌症研究机构 - 世界卫生组织头颈细胞病理学报告系统(WHO)和唾液腺细胞病理学米兰报告系统(MSRSGC)进行了比较分析。
对在巴黎居里研究所收集的2218份唾液腺细针穿刺样本(1954 - 2022年)进行评估,其中1356份有组织学随访。样本根据MSRSGC(非诊断性[ND]、非肿瘤性[NN]、意义未明的异型性[AUS]、良性肿瘤[BN]、恶性潜能不确定的唾液腺肿瘤[SUMP]、可疑恶性[SM]和恶性[M])以及WHO系统(不足/不充分/非诊断性、良性、非典型性、恶性潜能不确定的肿瘤[NUMP]、可疑恶性[SM]和恶性[M])进行分类。计算每个类别的恶性风险(ROM),并评估诊断性能指标。
在MSRSGC中,ROM分别为:ND,50%(n = 2);NN,16.8%(n = 149);AUS(无病例);BN,4.3%(n = 514);SUMP,50%(n = 2);SM,56.1%(n = 66);M,98.2%(n = 623)。在WHO系统中,ROM分别为:不足/不充分/非诊断性,50%(n = 2);良性,7.1%(n = 663);非典型性(无病例);NUMP,50%(n = 2);SM,56.1%(n = 66);M,98.2%(n = 623)。WHO的“良性”类别将NN和BN合并,将NN较高的ROM(16.8%)和BN较低的ROM(4.3%)平衡为7.1%。排除ND和SUMP/NUMP类别后,两个系统均显示出较高的诊断性能:敏感性为93.3%;特异性为93.9%;阳性预测值为94.2%;阴性预测值为92.9%。
两个系统都能有效地识别恶性肿瘤。WHO系统将NN和BN合并为良性类别简化了报告并减少了变异性,尽管这可能掩盖非肿瘤性和良性肿瘤性病变之间临床上的显著差异。